Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086712 | 0.79 | CA1 (0.33) | CA12CA14LMNAKMT2ACA1 | |
| SCHEMBL5706172 | 0.75 | DGAT1 (0.39) | CA12CA14LMNAKMT2ACA1 | |
| SCHEMBL11207906 | 0.75 | — | — | |
| SCHEMBL250780 | 0.75 | — | — | |
| SCHEMBL26328504 | 0.75 | CA12 (0.35) | CA12CA14LMNAKMT2ACA1 | |
| SCHEMBL9738701 | 0.74 | LMNA (0.33) | LMNAKMT2A | |
| SCHEMBL2992403 | 0.74 | CTSS (0.34) | CTSSCTSK | |
| SCHEMBL17093771 | 0.73 | NOS1 (0.36) | CA12CA14LMNAKMT2ACA1 | |
| SCHEMBL7277018 | 0.73 | CA12 (0.34) | CA12CA14LMNAKMT2ACA1 | |
| SCHEMBL10526055 | 0.73 | CA1 (0.37) | CA12CA14LMNAKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | NOVARTIS AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-11208398-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| CN-112513025-A | Chemical process for the preparation of phenylpiperidinylindole derivatives | 诺华股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-7572898-B2 | Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | SCINOPHARM TAIWAN, LTD. (TW) | 2009-08-11 | — | — | US | disclosed |
| EP-1891087-A4 | PROCESS OF MAKING AN ALPHA-ANOMER ENRICHED 2-DEOXY-2,2-DIFLOURO-D-RIBOFURANOSYL SULFONATE AND USE THEREOF FOR MAKING A BETA NUCLEOSIDE | SCINOPHARM TAIWAN LTD (TW) | 2008-07-30 | — | — | EP | disclosed |
| EP-1891087-A1 | PROCESS OF MAKING AN ALPHA-ANOMER ENRICHED 2-DEOXY-2,2-DIFLOURO-D-RIBOFURANOSYL SULFONATE AND USE THEREOF FOR MAKING A BETA NUCLEOSIDE | ScinoPharm Taiwan, Ltd. (TW) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006132808-A1 | PROCESS OF MAKING AN ALPHA-ANOMER ENRICHED 2-DEOXY-2,2-DIFLOURO-D-RIBOFURANOSYL SULFONATE AND USE THEREOF FOR MAKING A BETA NUCLEOSIDE | SCINOPHARM TAIWAN, LTD. (TW) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276638-A1 | Process of making an alpha-anomer enriched 2-deoxy-2,2-diflouro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | SCINOPHARM TAIWAN, LTD. | 2006-12-07 | — | — | US | disclosed |
| US-5256798-A | Treating beta-anomer ribofuranosyl sulfonate with source of conjugate anion | ELI LILLY AND COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-5252731-A | Antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5110921-A | Bactericides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| US-5051502-A | Process for forming antibiotics | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1991-09-24 | — | — | US | disclosed |
| US-4960889-A | CEPHALOSPORIN INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| US-4731443-A | 7-acylamino-3-vinylcephalosporanic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| EP-0046712-A1 | Fluorinated diaminobutane derivatives | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-03-03 | — | — | EP | disclosed |
| US-4071681-A | Process for preparing beta-lactam antibiotic substances | SANKYO COMPANY LIMITED (JA) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276638-A1 | Process of making an alpha-anomer enriched 2-deoxy-2,2-diflouro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside | DAD1, DEGS1, DUS2 | CA12 180/4885CA14 437/4885LMNA 2229/4885 |
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | IDO1, CYP3A7, PAH | CA12 3054/4885CA14 2120/4885LMNA 3641/4885 |
| US-11208398-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | CYP3A7, CYP3A5, IDO1 | CA12 3192/4885CA14 2308/4885LMNA 3569/4885 |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | IDO1, CYP3A7, PAH | CA12 3054/4885CA14 2120/4885LMNA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.